- Home
- ACRS vs FLC Comparison
ACRS vs FLC Comparison
Compare ACRS & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- FLC
- Stock Information
- Founded
- ACRS 2012
- FLC 2003
- Country
- ACRS United States
- FLC United States
- Employees
- ACRS N/A
- FLC N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- FLC Trusts Except Educational Religious and Charitable
- Sector
- ACRS Health Care
- FLC Finance
- Exchange
- ACRS Nasdaq
- FLC Nasdaq
- Market Cap
- ACRS 198.2M
- FLC 186.8M
- IPO Year
- ACRS 2015
- FLC N/A
- Fundamental
- Price
- ACRS $1.89
- FLC N/A
- Analyst Decision
- ACRS Strong Buy
- FLC
- Analyst Count
- ACRS 9
- FLC 0
- Target Price
- ACRS $9.25
- FLC N/A
- AVG Volume (30 Days)
- ACRS 1.1M
- FLC 37.8K
- Earning Date
- ACRS 11-05-2025
- FLC 01-01-0001
- Dividend Yield
- ACRS N/A
- FLC 6.64%
- EPS Growth
- ACRS N/A
- FLC N/A
- EPS
- ACRS N/A
- FLC N/A
- Revenue
- ACRS $16,789,000.00
- FLC N/A
- Revenue This Year
- ACRS N/A
- FLC N/A
- Revenue Next Year
- ACRS $7.02
- FLC N/A
- P/E Ratio
- ACRS N/A
- FLC N/A
- Revenue Growth
- ACRS N/A
- FLC N/A
- 52 Week Low
- ACRS $1.05
- FLC $12.62
- 52 Week High
- ACRS $5.17
- FLC $15.45
- Technical
- Relative Strength Index (RSI)
- ACRS 48.51
- FLC N/A
- Support Level
- ACRS $1.81
- FLC N/A
- Resistance Level
- ACRS $1.94
- FLC N/A
- Average True Range (ATR)
- ACRS 0.09
- FLC 0.00
- MACD
- ACRS -0.01
- FLC 0.00
- Stochastic Oscillator
- ACRS 27.51
- FLC 0.00
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.